Detection of Circulating Tumor Cells and Their Implications as a Biomarker for Diagnosis, Prognostication, and Therapeutic Monitoring in Hepatocellular Carcinoma

Autor: Pin-Jung Chen, Shelly C. Lu, Joseph C. Ahn, Hsian-Rong Tseng, Edwin M. Posadas, Ju Dong Yang, Pai-Chi Teng
Rok vydání: 2021
Předmět:
0301 basic medicine
Oncology
Medical Biochemistry and Metabolomics
Neoplastic Cells
0302 clinical medicine
Circulating tumor cell
Circulating
Cancer
screening and diagnosis
Tumor
medicine.diagnostic_test
Liver Disease
Liver Neoplasms
Epithelial Cell Adhesion Molecule
Neoplastic Cells
Circulating
Prognosis
Detection
Liver biopsy
Hepatocellular carcinoma
Biomarker (medicine)
030211 gastroenterology & hepatology
Biotechnology
4.2 Evaluation of markers and technologies
Liver Cancer
medicine.medical_specialty
Carcinoma
Hepatocellular
Clinical Sciences
Immunology
Article
03 medical and health sciences
Rare Diseases
Clinical Research
Internal medicine
Biomarkers
Tumor
medicine
Carcinoma
Humans
Liquid biopsy
Gastroenterology & Hepatology
Hepatology
business.industry
Liquid Biopsy
Hepatocellular
medicine.disease
Precision medicine
digestive system diseases
4.1 Discovery and preclinical testing of markers and technologies
Review article
Good Health and Well Being
030104 developmental biology
Digestive Diseases
business
Biomarkers
Zdroj: Hepatology
Hepatology (Baltimore, Md.), vol 73, iss 1
ISSN: 1527-3350
0270-9139
DOI: 10.1002/hep.31165
Popis: Hepatocellular carcinoma (HCC) is among the leading causes of worldwide cancer-related morbidity and mortality. Poor prognosis of HCC is mainly attributed to tumor presentation at an advanced stage when there is no effective treatment to achieve the long term survival of patients. Currently available tests such as alpha-fetoprotein (AFP) have limited accuracy as a diagnostic or prognostic biomarker for HCC. Liver biopsy provides tissue that can reveal tumor biology but it is not used routinely due to its invasiveness and risk of tumor seeding, especially in early stage patients. Liver biopsy is also limited in revealing comprehensive tumor biology due to intra-tumoral heterogeneity. There is a clear need for new biomarkers to improve HCC detection, prognostication, prediction of treatment response, and disease monitoring with treatment. Liquid biopsy could be an effective method of early detection and management of HCC. Circulating tumor cells (CTCs) are cancer cells in circulation derived from the original tumor or metastatic foci, and their measurement by liquid biopsy represents a great potential to facilitate the implementation of precision medicine in patients with HCC. CTCs can be detected by a simple peripheral blood draw and potentially show global features of tumor characteristics. Various CTC detection platforms utilizing immunoaffinity and biophysical properties have been developed in order to identify and capture CTCs with high efficiency. Quantitative abundance of CTCs, as well as biological characteristics and genomic heterogeneity among the CTCs, can predict disease prognosis and response to therapy in patients with HCC. This review article will discuss the currently available technologies for CTC detection and isolation, their utility in the clinical management of HCC patients, their limitations, and future directions of research.
Databáze: OpenAIRE
Externí odkaz: